| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 32 |
| 1 | FOLIC ACID | 17 |
| 2 | CYCLOPHOSPHAMIDE | 16 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 16 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 16 |
| 5 | PREDNISONE | 16 |
| 6 | METHOTREXATE SODIUM | 14 |
| 7 | TACROLIMUS | 14 |
| 8 | METHOTREXATE | 13 |
| 9 | RITUXIMAB-ABBS | 13 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SUTIMLIMAB-JOME | 2 | 0.0062 |
| 1 | DORAVIRINE | 3 | 0.0038 |
| 2 | RITUXIMAB-ABBS | 13 | 0.0025 |
| 3 | HALOPERIDOL DECANOATE | 3 | 0.0017 |
| 4 | IPTACOPAN | 1 | 0.0013 |
| 5 | AMIFOSTINE | 1 | 0.0012 |
| 6 | TREOSULFAN | 3 | 0.0011 |
| 7 | CARMUSTINE | 4 | 0.0008 |
| 8 | PENTAMIDINE ISETHIONATE | 1 | 0.0008 |
| 9 | LOXAPINE | 3 | 0.0008 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 45 |
| 1 | Corticosteroid [EPC] | 39 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 20 |
| 3 | Alkylating Drug [EPC] | 19 |
| 4 | Vitamin C [EPC] | 18 |
| 5 | Kinase Inhibitor [EPC] | 17 |
| 6 | Platinum-based Drug [EPC] | 17 |
| 7 | Vitamin B12 [EPC] | 17 |
| 8 | Vitamin D [EPC] | 17 |
| 9 | Benzodiazepine [EPC] | 13 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Classical Complement Pathway Inhibitor [EPC] | 2 | 0.0062 |
| 1 | CD52-directed Cytolytic Antibody [EPC] | 4 | 0.0002 |
| 2 | CD30-directed Immunoconjugate [EPC] | 2 | 0.0002 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 45 | 0.0001 |
| 4 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 3 | 0.0001 |
| 5 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 6 | Thyroid Hormone Synthesis Inhibitor [EPC] | 1 | 0.0001 |
| 7 | Complement Inhibitor [EPC] | 5 | 0.0001 |
| 8 | CTLA-4-directed Blocking Antibody [EPC] | 4 | 0.0001 |
| 9 | Alkylating Drug [EPC] | 19 | 0.0001 |